Treatment with Isorhamnetin Protects the Brain Against Ischemic Injury in Mice

Neurochemical Research

Volumn 41, Issue 8, 2016, Pages 1939-1948

  Zhao, Jin Jing ^a   Song, Jin Qing ^b   Pan, Shu Yi ^c   Wang, Kai ^a  

^a The 305 Hospital of Chinese PLA   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c NAVY GENERAL HOSPITAL   (China)

Author keywords

Edema; Inflammation; Ischemic stroke; Isorhamnetin; Oxidative stress

Indexed keywords

CASPASE 3; CLAUDIN 5; HEME OXYGENASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISORHAMNETIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; NEUROPROTECTIVE AGENT; OCCLUDIN; TIGHT JUNCTION PROTEIN; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; 3-METHYLQUERCETIN; QUERCETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN INFARCTION SIZE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL CEREBRAL ISCHEMIA; GENE EXPRESSION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; LASER DOPPLER FLOWMETRY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ROTAROD TEST; SENSORIMOTOR FUNCTION; TRANSIENT FOCAL CEREBRAL ISCHEMIA; TREATMENT RESPONSE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; BRAIN ISCHEMIA; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; BRAIN; BRAIN ISCHEMIA; MALE; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; QUERCETIN; TREATMENT OUTCOME;

EID: 84966546691     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-016-1904-2     Document Type: Article

References (42)

1. Lavados PM, Hennis AJ, Fernandes JG, Medina MT, Legetic B, Hoppe A, Sacks C, Jadue L, Salinas R (2007) Stroke epidemiology, prevention, and management strategies at a regional level: Latin America and the Caribbean. Lancet Neurol 6:362–372
2. Mukherjee D, Patil CG (2011) Epidemiology and the global burden of stroke. World Neurosurg 76(6 Suppl):S85–S90
3. Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV (2011) Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener 6:11
4. Tsai CF, Thomas B, Sudlow CL (2013) Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology 81:264–272
5. Zhao YZ, Yao Z, D’Souza W, Zhu C, Chun H, Zhuoga C, Zhang Q, Hu X, Zhou D (2010) An epidemiological survey of stroke in Lhasa, Tibet, China. Stroke 41:2739–2743
6. Park JC, Young HS, Yu YB, Lee JH (1995) Isorhamnetin sulphate from the leaves and stems of Oenanthe javanica in Korea. Planta Med 61:377–378
7. Wiczkowski W, Skipor J, Misztal T, Szawara-Nowak D, Topolska J, Piskula MK (2015) Quercetin and isorhamnetin aglycones are the main metabolites of dietary quercetin in cerebrospinal fluid. Mol Nutr Food Res 59:1088–1094
8. Boesch-Saadatmandi C, Egert S, Schrader C, Coumoul X, Barouki R, Muller MJ, Wolffram S, Rimbach G (2010) Effect of quercetin on paraoxonase 1 activity—studies in cultured cells, mice and humans. J Physiol Pharmacol 61:99–105
9. 2-induced activation of the intrinsic apoptotic pathway in H9c2 cardiomyocytes through scavenging reactive oxygen species and ERK inactivation. J Cell Biochem 113:473–485
10. Zhang N, Pei F, Wei H, Zhang T, Yang C, Ma G, Yang C (2011) Isorhamnetin protects rat ventricular myocytes from ischemia and reperfusion injury. Exp Toxicol Pathol 63:33–38
11. Li W, Chen Z, Yan M, He P, Chen Z, Dai H (2016) The protective role of isorhamnetin on human brain microvascular endothelial cells from cytotoxicity induced by methylglyoxal and oxygen glucose deprivation. J Neurochem 136:651–659
12. Jackman K, Kunz A, Iadecola C (2011) Modeling focal cerebral ischemia in vivo. Methods Mol Biol 793:195–209
13. Hochrainer K, Jackman K, Anrather J, Iadecola C (2012) Reperfusion rather than ischemia drives the formation of ubiquitin aggregates after middle cerebral artery occlusion. Stroke 43:2229–2235
14. Sun J, Sun G, Meng X, Wang H, Luo Y, Qin M, Ma B, Wang M, Cai D, Guo P, Sun X (2013) Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. PLoS ONE 8:e64526
15. Zhang W, Hu X, Yang W, Gao Y, Chen J (2010) Omega-3 polyunsaturated fatty acid supplementation confers long-term neuroprotection against neonatal hypoxic-ischemic brain injury through anti-inflammatory actions. Stroke 41:2341–2347
16. Cetin F, Yazihan N, Dincer S, Akbulut G (2013) The effect of intracerebroventricular injection of beta amyloid peptide (1–42) on caspase-3 activity, lipid peroxidation, nitric oxide and NOS expression in young adult and aged rat brain. Turk Neurosurg 23:144–150
17. Zeynalov E, Jones SM, Seo JW, Snell LD, Elliott JP (2015) Arginine-vasopressin receptor blocker conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in mice. PLoS ONE 10:e0136121
18. Zeynalov E, Chen CH, Froehner SC, Adams ME, Ottersen OP, Amiry-Moghaddam M, Bhardwaj A (2008) The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema. Crit Care Med 36:2634–2640
19. Weifeng Y, Li L, Yujie H, Weifeng L, Zhenhui G, Wenjie H (2016) Inhibition of acute lung injury by TNFR-Fc through regulation of an inflammation-oxidative stress pathway. PLoS ONE 11:e0151672
20. Wu F, Feng JZ, Qiu YH, Yu FB, Zhang JZ, Zhou W, Yu F, Wang GK, An LN, Ni FH, Wu H, Zhao XX, Qin YW, Luo HD (2013) Activation of receptor for advanced glycation end products contributes to aortic remodeling and endothelial dysfunction in sinoaortic denervated rats. Atherosclerosis 229:287–294
21. Choi BM, Pae HO, Chung HT (2003) Nitric oxide priming protects nitric oxide-mediated apoptosis via heme-oxygenase-1 induction. Free Radic Biol Med 34:1136–1145
22. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206–209
23. Hillegass LM, Griswold DE, Brickson B, Albrightson-Winslow C (1990) Assessment of myeloperoxidase activity in whole rat kidney. J Pharmacol Methods 24:285–295
24. Yang Y, Rosenberg GA (2011) Blood–brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 42:3323–3328
25. Nag S, Manias JL, Stewart DJ (2009) Pathology and new players in the pathogenesis of brain edema. Acta Neuropathol 118:197–217
26. Gerriets T, Walberer M, Ritschel N, Tschernatsch M, Mueller C, Bachmann G, Schoenburg M, Kaps M, Nedelmann M (2009) Edema formation in the hyperacute phase of ischemic stroke. Laboratory investigation. J Neurosurg 111:1036–1042
27. Wolburg H, Lippoldt A (2002) Tight junctions of the blood–brain barrier: development, composition and regulation. Vascul Pharmacol 38:323–337
28. Rodrigo R, Fernández-Gajardo R, Gutiérrez R, Matamala JM, Carrasco R, Miranda-Merchak A, Feuerhake W (2013) Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities. CNS Neurol Disord: Drug Targets 12:698–714
29. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13:76–86
30. Shih AY, Li P, Murphy TH (2005) A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci 25:10321–10335
31. Yang JH, Shin BY, Han JY, Kim MG, Wi JE, Kim YW, Cho IJ, Kim SC, Shin SM, Ki SH (2014) Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicol Appl Pharmacol 274:293–301
32. Pérez-Asensio FJ, Hurtado O, Burguete MC, Moro MA, Salom JB, Lizasoain I, Torregrosa G, Leza JC, Alborch E, Castillo J, Knowles RG, Lorenzo P (2005) Inhibition of iNOS activity by 1400 W decreases glutamate release and ameliorates stroke outcome after experimental ischemia. Neurobiol Dis 18:375–384
33. Christopherson KS, Bredt DS (1997) Nitric oxide in excitable tissues: physiological roles and disease. J Clin Invest 100:2424–2429
34. Reiter RJ, Tan DX, Manchester LC, Qi W (2001) Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 34:237–256
35. Simats A, García-Berrocoso T, Montaner J (2016) Neuroinflammatory biomarkers: from stroke diagnosis and prognosis to therapy. Biochim Biophys Acta 1862:411–424
36. Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. Nat Med 17:796–808
37. Yenari MA, Kunis D, Sun GH, Onley D, Watson L, Turner S, Whitaker S, Steinberg GK (1998) Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Exp Neurol 153:223–233
38. Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR (2015) Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J Cereb Blood Flow Metab 35:888–901
39. Weilinger NL, Maslieieva V, Bialecki J, Sridharan SS, Tang PL, Thompson RJ (2013) Ionotropic receptors and ion channels in ischemic neuronal death and dysfunction. Acta Pharm Sinica 34:39–48
40. Arundine M, Tymianski M (2003) Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 34:325–327
41. Simon RP, Swan JH, Griffiths T, Meldrum BS (1984) Blockade of N-methyl-d-aspartate receptors may protect against ischemic damage in the brain. Science 226:850–852
42. Takahashi H, Xia P, Cui J, Talantova M, Bodhinathan K, Li W, Holland EA, Tong G, Piña-Crespo J, Zhang D, Nakanishi N, Larrick JW, McKercher SR, Nakamura T, Wang Y, Lipton SA (2015) Pharmacologically targeted NMDA receptor antagonism by nitromemantine for cerebrovascular disease. Sci Rep 5:14781